Cholesteryl ster transfer protein inhibitors, pharmaceutical compositions
containing such inhibitors and the use of such inhibitors to elevate certain plasma
lipid levels, including high density lipoprotein-cholesterol and to lower certain
other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly
to treat diseases which are exacerbated by low levels of HDL cholesterol and/or
high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular
diseases in some mammals, including humans.
